These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 25296748

  • 1. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T, Ishizaki T, Hosoya T, Iga S, Yokoyama W, Hirano F, Miyasaka N, Harigai M.
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [Abstract] [Full Text] [Related]

  • 2. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T.
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [Abstract] [Full Text] [Related]

  • 3. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
    Ruyssen-Witrand A, Guernec G, Nigon D, Tobon G, Jamard B, Rat AC, Vittecoq O, Cantagrel A, Constantin A.
    Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
    [Abstract] [Full Text] [Related]

  • 4. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.
    Koga T, Okada A, Fukuda T, Hidaka T, Ishii T, Ueki Y, Kodera T, Nakashima M, Takahashi Y, Honda S, Horai Y, Watanabe R, Okuno H, Aramaki T, Izumiyama T, Takai O, Miyashita T, Sato S, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Origuchi T, Nakamura H, Aoyagi K, Eguchi K, Kawakami A, Japanese RA Patients with RRP Study Group.
    PLoS One; 2017 Sep; 12(5):e0175281. PubMed ID: 28505163
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM.
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM, Halland AM, Brzosko M, Burgos-Vargas R, Mela C, Vernon E, Kremer JM.
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [Abstract] [Full Text] [Related]

  • 7. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E, Gabay C, Finckh A, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [Abstract] [Full Text] [Related]

  • 8. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

  • 9. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
    Kawashiri SY, Nishino A, Suzuki T, Nakashima Y, Horai Y, Ueki Y, Aramaki T, Fujikawa K, Nakashima M, Okada A, Migita K, Mizokami A, Matsuoka N, Mine M, Sakito S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Aoyagi K, Eguchi K, Kawakami A.
    Clin Exp Rheumatol; 2016 Dec; 34(5):808-812. PubMed ID: 27384149
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 12. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [Abstract] [Full Text] [Related]

  • 17. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N.
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [Abstract] [Full Text] [Related]

  • 18. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2162-2169. PubMed ID: 31155669
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML.
    Dan Med Bull; 2011 Nov 01; 58(11):B4320. PubMed ID: 22047935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.